Outcome Measure	Evidence	Implications
Disease-oriented Evidence	Clinical trials	Riociguat has been shown to be safe and effective in improving hemodynamics, exercise capacity, functional class, and dyspnea scores Improved clinical outcomes have been consistently demonstrated over an extended period of time
Patient-oriented Evidence	Clinical trials	Riociguat has demonstrated improved quality-of-life Has been shown to be well tolerated Patients should be monitored for hypotension during dose titration.
Economic Evidence	Prospective cohort, Cost-utility analysis, and Budget-impact analysis	Drug-related cost is insignificant Riociguat is less costly and more cost-effective when compared to Bosentan